ArticleMethods in molecular biology (Clifton, N.J.)2025
Metabolomics of the Kynurenine Pathway by Laser Desorption Ionization Mass Spectrometry (LDI-MS).
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kynurenine (KYN) pathway is a branch of tryptophan metabolic cascade. The KYN pathway is unique since it generates multiple neuroactive metabolites, including 3-hydroxykynurenine (3-HK), kynurenic acid (KYNA), quinolinic acid (QUIN), and picolinic acid (PIC). Whereas KYNA and PIC are neuroprotective, 3-HK and QUIN are potently neurotoxic and attribute to major neurodegenerative diseases like schizophrenia, Alzheimer's disease, Huntington's disease, bipolar disorder, and depression. It is increasingly evident that the ratio(s) between the neurotoxic versus neuroprotective metabolites may help predict the manifestations of disease versus health. Therefore, high-throughput platforms for determining the relative levels of these kynurenine metabolites in biofluids offer considerable potential. Current analytical tools for studying the KYN pathway include assays of branching enzymes, PCR, immunoanalysis, and liquid chromatography-mass spectrometry. Neither of these offers high-throughput, cost-effective analyses suited for clinical or drug-screening applications. In this report, a Laser Desorption Ionization Mass Spectrometry (LDI-MS) method is described using SBA-15 mesoporous silica. The system allows fast, high-resolution relative quantitation of neurotoxic kynurenines using targeted metabolomics on conventional Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (mass spectrometry) (MALDI-TOF) platforms.
Indexed as
Identifiers
40498190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.